Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.55 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169540 | 0.87 | KIF11 (0.49) | KIF11ACSS2HDAC3HDAC4HDAC1 | |
| SCHEMBL6171451 | 0.85 | NPC1 (0.63) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6169166 | 0.83 | PPARG (0.57) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6171124 | 0.82 | ACSS2 (0.47) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6169569 | 0.81 | EPHX2 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6170762 | 0.81 | AGTR1 (0.54) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6169195 | 0.81 | TNF (0.62) | ACSS2HDAC1HDAC6GALR3NR2F2 | |
| SCHEMBL6169918 | 0.80 | LMNA (0.47) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6308864 | 0.80 | PPARG (0.50) | ACSS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6169600 | 0.80 | HDAC1 (0.52) | ACSS2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | KIF11 4110/4885ACSS2 1260/4885HDAC3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.